Fresenius Medical Care : On track for 2025 targets – incorporating higher headwinds
>Q4 preview – strong finish of a better-than-expected year - Q4 revenues of € 4,930m (-1.3% y-o-y) should profit from organic growth of 4.3%, but suffer from divestments of 70bp and forex headwind of 490bp. We forecast revenues of € 3,897m (-2.4% y-o-y) for Care delivery impacted by the exit of some international markets. For Care enablement, we predict revenues of € 1,399m (+0.5% y-o-y) supported by organic growth of 5.3%. Q4 EBIT is expected to reach a strong ...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.